Kiniksa (KNSA) CFO Exercise and Sale Disclosed in Form 4

Rhea-AI Filing Summary

Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals International (KNSA), reported multiple equity transactions from September 1–3, 2025. The filings show a series of restricted share unit (RSU) grants, option exercises and open-market trades executed pursuant to a 10b5-1 plan. On September 3, 2025 the reporting person exercised a share option for 11,000 Class A Ordinary Shares at an exercise price of $17.92 and sold 11,000 shares in the market at a weighted average price of $34.84. Several RSU awards and stock options were granted or recognized on September 1–2, 2025 with various vesting schedules; one option grant has an exercise price of $33.49 and expires August 31, 2035. Following the reported transactions the reporting person beneficially owned 38,011 Class A Ordinary Shares.

Positive

• Full disclosure of transactions including exercise prices, weighted average sale price, and vesting schedules
• Use of a 10b5-1 trading plan is explicitly disclosed, indicating pre-arranged trading intent
• Detailed vesting terms for RSUs and options are provided, clarifying future equity dilution timing

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider exercise and sale under a 10b5-1 plan; not unusually dilutive or unexpected.

The form indicates a typical pattern where an insider exercises vested options at $17.92 and immediately sells the underlying shares at a higher market price via a pre-established 10b5-1 plan. The sale of 11,000 shares at a weighted average of $34.84 realized a spread versus the exercise price, while the filing also documents newly recognized RSUs and an option grant with a $33.49 exercise price expiring in 2035. These transactions are descriptive of compensation monetization and standard equity compensation administration rather than extraordinary corporate events.

Corporate Governance Expert

TL;DR: Transactions follow standard governance practices with a disclosed 10b5-1 plan and documented vesting terms.

The report clearly discloses the reporting persons relationship to the issuer as Chief Accounting Officer and shows use of a 10b5-1 trading plan executed July 24, 2024. Vesting schedules for multiple RSU grants and option vesting commencement dates are specified, and the option exercised on September 3, 2025 is noted as fully vested where applicable. Disclosure meets Section 16 reporting norms and provides necessary vesting and expiration details for oversight.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Megna Michael R

(Last) (First) (Middle)

23 OLD BOND STREET, THIRD FLOOR

(Street)

LONDON X0 W1S 4PZ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF ACCOUNTING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	09/01/2025		M		2,363	A	(1)	35,404	D
Class A Ordinary Share	09/01/2025		M		2,557	A	(1)	37,961	D
Class A Ordinary Share	09/01/2025		M		3,933	A	(1)	41,894	D
Class A Ordinary Share	09/01/2025		F		4,282	D	$33.49	37,612	D
Class A Ordinary Share	09/02/2025		M		774	A	(1)	38,386	D
Class A Ordinary Share	09/02/2025		F		375	D	$34.28	38,011	D
Class A Ordinary Share	09/03/2025		M(2)		11,000	A	$17.92	49,011	D
Class A Ordinary Share	09/03/2025		S(2)		11,000	D	$34.84(3)	38,011	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Unit	(1)	09/01/2025		A		10,575		(4)	(4)	Class A Ordinary Share	10,575	$0	10,575	D
Share Option	$33.49	09/01/2025		A		21,150		(5)	08/31/2035	Class A Ordinary Share	21,150	$0	21,150	D
Restricted Share Unit	(1)	09/01/2025		M			2,363	(6)	(6)	Class A Ordinary Share	2,363	$0	7,087	D
Restricted Share Unit	(1)	09/01/2025		M			2,557	(7)	(7)	Class A Ordinary Share	2,557	$0	5,115	D
Restricted Share Unit	(1)	09/01/2025		M			3,933	(8)	(8)	Class A Ordinary Share	3,933	$0	3,932	D
Restricted Share Unit	(1)	09/02/2025		M			774	(9)	(9)	Class A Ordinary Share	774	$0	0	D
Share Option	$17.92	09/03/2025		M(2)			11,000	(10)	03/03/2029	Class A Ordinary Share	11,000	$0	0	D

Explanation of Responses:

1. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

2. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 24, 2024.

3. This transaction was executed in multiple trades through a broker-dealer at prices ranging between $34.80 and $35.005. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

4. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.

5. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025.

6. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024.

7. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.

8. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.

9. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021.

10. The option is fully vested and Exercisable.

	/s/ Aaron Young, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider traded shares of KNSA according to this Form 4?

The reporting person is Michael R. Megna, Chief Accounting Officer of Kiniksa Pharmaceuticals (KNSA).

How many shares were sold and at what price on September 3, 2025?

The filer sold 11,000 Class A Ordinary Shares at a weighted average price of $34.84.

Did the reporting person exercise any options?

Yes, on September 3, 2025 the reporting person exercised an option for 11,000 shares at an exercise price of $17.92.

Was a 10b5-1 plan used for any transactions?

Yes, certain transactions were effectuated pursuant to a 10b5-1 plan executed July 24, 2024.

What is the reporting persons beneficial ownership after these transactions?

Following the reported transactions the reporting person beneficially owned 38,011 Class A Ordinary Shares.

Are there any long-dated option grants disclosed?

Yes, an option grant with an exercise price of $33.49 was reported that expires on August 31, 2035.